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ABSTRACT
OBJECTIVES The authors report 1-year outcomes of high-risk patients with failed surgical annuloplasty rings under-
going transseptal mitral valve–in–ring (MViR) with the SAPIEN 3 aortic transcatheter heart valve (THV).
BACKGROUND The MITRAL (Mitral Implantation of Transcatheter Valves) trial is the first prospective study evaluating
transseptal MViR with the SAPIEN 3 aortic THV in high-risk patients with failed surgical annuloplasty rings.
METHODS Prospective enrollment of high-risk patients with symptomatic moderate to severe or severe mitral regur-
gitation (MR) or severe mitral stenosis and failed annuloplasty rings at 13 U.S. sites. The primary safety endpoint was
technical success. The primary THV performance endpoint was absence of MR grade $2þ or mean mitral valve
gradient $10 mm Hg (30 days and 1 year). Secondary endpoints included procedural success and all-cause mortality
(30 days and 1 year).
RESULTS Thirty patients were enrolled between January 2016 and October 2017 (median age 71.5 years [interquartile
range: 67.0 to 76.8 years], 36.7% women, median Society of Thoracic Surgeons score 7.6% [interquartile range: 5.1% to
11.8%], 76.7% in New York Heart Association functional class III or IV). Technical success was 66.7% (driven primarily by
need for a second valve in 6 patients). There was no intraprocedural mortality or conversion to surgery. The primary
performance endpoint was achieved in 85.7% of survivors at 30 days (24 of 28) and 89.5% of patients alive at 1 year with
echocardiographic data available (17 of 19). All-cause mortality at 30 days was 6.7% and at 1 year was 23.3%. Among
survivors at 1-year follow-up, 84.2% were in New York Heart Association functional class I or II, the median mean mitral
valve gradient was 6.0 mm Hg (interquartile range: 4.7 to 7.3 mm Hg), and all had #1þ MR.
CONCLUSIONS Transseptal MViR was associated with a 30-day mortality rate lower than predicted by the Society of
Thoracic Surgeons score. At 1 year, transseptal MViR was associated with symptom improvement and stable THV per-
formance. (J Am Coll Cardiol Intv 2021;14:846–58) © 2021 by the American College of Cardiology Foundation.
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D espite increases in surgical volumes andexperience, contemporary 30-day mortalityrelated to repeat mitral surgery remains
higher (11.1%) than that associated with a first mitral
valve (MV) operation (6.5%; p < 0.0001) (1).
Transcatheter MV replacement (TMVR) using
balloon-expandable aortic transcatheter heart valves
(THVs) has emerged as an alternative to surgery for
patients with severe MV disease due to failed surgical
repairs with annuloplasty rings, among those who are
not good candidates for conventional MV surgery.
Retrospective registries collecting early experience of
mitral valve-in-ring (MViR) procedures using the SA-
PIEN family of aortic THVs (Edwards Lifesciences,
Irvine, California) in patients at high surgical risk
have shown that MViR is feasible with reasonable
outcomes. The 30-day mortality rate in the early
experience of the VIVID (Valve in Valve International
Data) registry was 11.4% and in the STS/ACC TVT
(Society of Thoracic Surgeons/American College of
Cardiology Transcatheter Valve Therapy) Registry
was 11.5% (2,3). These 2 registries collected early
experience, including first- and second-generation
devices and a large proportion of transapical access.
Whether newer generation devices and/or the use of
transseptal access will result in improved outcomes is
not known. A prospective clinical trial had not been
performed prior to our study. The aim of the MViR
arm of the MITRAL (Mitral Implantation of Trans-
catheter Valves) trial (IDE G140136; NCT02370511) is
to prospectively evaluate the safety and feasibility of
transseptal MViR using the third-generation SAPIEN 3
valve in patients who are not candidates for conven-
tional redo mitral surgery. We present herein the 1-
year outcomes of MViR in this trial.
METHODS
The MITRAL early feasibility study is a physician-
initiated, prospective, multicenter, clinical trial
designed to evaluate the safety and feasibility of TMVR
using the SAPIEN XT and SAPIEN 3 valves. The study
has 3 treatment arms: native MV disease with severe
mitral annular calcification (MAC) treated with
valve-in-MAC procedures, failing surgical repairs
with annuloplasty rings treated with MViR, and mitral
valve-in-valve (MViV) in failed surgical bio-
prostheses. A total of 91 patients at high sur-
gical risk were enrolled (valve-in-MAC, n ¼ 31;
MViR, n ¼ 30; MViV, n ¼ 30) and treated be-
tween March 2015 and December 2017 at 13
sites in the United States. We present herein
the results of the MViR arm. Patients were
considered eligible for the study if they had
symptoms of New York Heart Association
functional class II or greater due to severe
mitral stenosis, defined as MV area 1.5 cm2 or
less by transthoracic echocardiography or at
least moderate to severe mitral regurgitation
(MR). A list of inclusion and exclusion criteria
is provided in Supplemental Appendix 1.
Candidates were presented in a live case-
review conference call to a subject eligibility
committee to determine eligibility. Baseline echo-
cardiograms and computed tomographic (CT) studies
were analyzed by independent core laboratories.
Clinical events were adjudicated by an independent
clinical events committee, and safety was monitored
by a data and safety monitoring board (Supplemental
Appendix 2). This study was conducted following
ethical principles according to the Declaration of
Helsinki as well as U.S. Food and Drug Administration
guidelines (Code of Federal Regulations Title 21, Part
812) and Good Clinical Practices recommended by the
International Organization for Standardization (ISO
14155:2011). The study was approved by the Mayo
Clinic Institutional Review Board and the respective
Institutional Review Boards of the participating in-
stitutions. All patients provided written informed
consent.
PROCEDURES. Transthoracic and transesophageal
echocardiograms were obtained according to pub-
lished guidelines and were analyzed at an indepen-
dent core laboratory according to the American
Society of Echocardiography standard for echocardi-
ography core laboratories (4,5). The cardiac CT image
acquisition protocol was similar to CT protocols for
transcatheter aortic valve replacement (6), with ad-
justments for MV analysis (7), summarized in
Supplemental Appendix 3 and illustrated in Figure 1.
Although the MViV software application was used in
the evaluation (8), THV size was selected according to
SEE PAGE 873
AB BR E V I A T I O N S
AND ACRONYM S
CT = computed tomographic
LVOT = left ventricular
outflow tract
MAC = mitral annular
calcification
MR = mitral regurgitation
MV = mitral valve
MVG = mitral valve gradient
MViR = mitral valve–in–ring
MViV = mitral valve–in–valve
THV = transcatheter heart
valve
TMVR = transcatheter mitral
valve replacement
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FIGURE 1 Cardiac Computed Tomographic Analysis
Measurements of mitral annulus made using 3mensio Structural Heart Workflow version 8.1 (Pie Medical Imaging, Maastricht, the Netherlands). (A) The
mitral valve “neo-annulus” area of surgical ring measurement is shown from the surgeon’s short-axis view during diastole (D-shape method). (B,C) A
virtual transcatheter heart valve (THV) is placed in the mitral surgical ring (pink), with size selected according to neo-annulus/surgical ring area. (D) The
virtual valve placed in the mitral annulus is visualized in the left ventricular outflow tract (LVOT) long-axis view. The LVOT space is measured at the site
where the THV stent frame is in closest proximity of the septum (arrow). (E) Neo-LVOT area measurement shown in short-axis view during systole. After
placing the virtual valve (pink), the remaining LVOT area is measured (white). (F) Fluoroscopic simulation of transseptal access (arrow) for procedural
planning purposes.
FIGURE 2 Patient Flowchart
LVOTO ¼ left ventricular outflow tract obstruction.
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the mitral neo-annulus area as determined by cardiac
CT analysis using a sizing chart, as done for trans-
catheter aortic valve replacement (7,9). All patients
were treated with transseptal access. The preferred
location for transseptal puncture was inferior and
posterior. Balloon septostomy for transseptal delivery
of the THV was performed using a 10- or 12-mm
balloon for the 23- and 26-mm SAPIEN 3 valves and
a 12- or 14-mm balloon for the 29-mm valve. The
technique for transseptal MViR is similar to the pre-
viously published transseptal MViV technique (7).
OUTCOMES. The primary safety endpoint was tech-
nical success at exit from the cardiac catheterization
laboratory, defined as successful delivery and
retrieval of the transcatheter delivery system,
deployment of a single valve in the correct position in
the mitral annulus, adequate performance of the THV
with residual MR <2þ and mean MV gradient
(MVG) <10 mm Hg, no need for surgery or additional
reintervention, and patient’s departure from the
procedure room alive. The primary THV performance
endpoint was absence of MR grade $2þ or mean
MVG $10 mm Hg at 30 days and 1 year. Secondary
safety endpoints included procedural success and all-
cause mortality at 30 days and 1 year. Definitions and
a complete list of secondary endpoints are provided
in Supplemental Appendix 4.
STATISTICAL ANALYSIS. Continuous variables are
summarized as median (interquartile range). Cate-
gorical variables are presented as frequencies and
percentages. Comparisons between time points were
made using a Wilcoxon test. Comparisons of mean
MVG between THV sizes were made using Kruskal-
Wallis 1-way analysis of variance on ranks. A
Kaplan-Meier curve was generated for all-cause
mortality and the composite endpoint of all-cause
mortality and hospitalization for heart failure. For
the purposes of this paper, all p values were 2-sided,
and values <0.05 were considered to indicate statis-
tical significance. All analyses were conducted using
R version 3.6.2 (R Foundation for Statistical
Computing, Vienna Austria).
RESULTS
Between January 2016 and October 2017, 36 subjects
were screened and presented at a case-review
TABLE 1 Baseline Patient Characteristics (n ¼ 30)
Age (yrs) 71.5 (67.0–76.8)
Female 11/30 (36.7)
Diabetes 9/30 (30)
Atrial fibrillation 21/30 (70)
Chronic kidney disease 10/30 (33.3)
Chronic obstructive pulmonary disease 6 /30 (20)
Home oxygen therapy 4/30 (13.3)
Receiving long-term anticoagulation 15/30 (50)
Hospitalization for heart failure during prior
12 months
9/30 (30)
Prior stroke 4/30 (13.3)
Prior CABG 19/30 (63.3)
Prior AVR 4/30 (13.3)
TAVR 1/4 (25)
SAVR 3/4 (75)
Type of surgical ring
Edwards Physio 9/30 (30)
Edwards Classic 4/30 (13.3)
S. Jude Seguin 3/30 (10)
Medtronic CG Future Ring 3/30 (10)
Medtronic CG Future Band 2/30 (6.7)
Edwards Physio 2 2/30 (6.7)
Edwards ET Logix 1/30 (3.3)
St. Jude Tailor Band 1/30 (3.3)
Medtronic Simulus SemiRigid 1/30 (3.3)
Duran AnCore 1/30 (3.3)
Sorin Memo 3D 1/30 (3.3)
Sorin Annuloflex 1/30 (3.3)
Cosgrove band 1/30 (3.3)






Values are median (interquartile range) or n/N (%).
AVR ¼ aortic valve replacement; CABG ¼ coronary artery bypass grafting;
MVR ¼ mitral valve replacement; NYHA ¼ New York Heart Association;
SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgeons;
TAVR ¼ transcatheter aortic valve replacement.
TABLE 2 Baseline Echocardiographic Characteristics (n ¼ 30)
Ejection fraction (%) 46.5 (33.4–55.6)
Stroke volume (ml) 64.6 (52.1–81.8)
Cardiac output (l/min) 5.2 (3.7–5.8)
Mean MVG (mm Hg) 6.2 (4.6–8.2)
MVA (cm2) 2.8 (2.3–3.2)
Pulmonary artery systolic pressure (mm Hg)* 46.5 (40.5–59.8)
Peak LVOT gradient (mm Hg) 3.3 (2.5–4.5)
Mean LVOT gradient (mm Hg) 1.6 (1.3–2.4)
Pathology (mode of ring failure)
Stenosis 10/30 (33.3)
Regurgitation 17/30 (56.7)
Both stenosis and regurgitation 3/30 (10)
Severity of mitral regurgitation
None or trace 5/30 (16.7)
1 (þ) 5/30 (16.7)
2 (þ) 12/30 (40.0)
3 (þ) 7/30 (23.3)
4 (þ) 1/30 (3.4)
Values are median (interquartile range) or n/N (%). *Five missing.
LVOT ¼ left ventricular outflow tract; MVA ¼ mitral valve area; MVG ¼ mitral
valve gradient.
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conference call for subject eligibility determination.
Six patients (16.7%) were excluded because of sus-
pected high risk for embolization associated with
incomplete rings (Cosgrove band, n ¼ 2; PeriGuard
band, n ¼ 1), risk for left ventricular outflow tract
(LVOT) obstruction (n ¼ 2), and prosthetic ring
dehiscence with pararing leak (n ¼ 1). Thirty patients
were enrolled (patient flow is illustrated in Figure 2).
Baseline clinical characteristics are presented in
Table 1. The median age was 71.5 years (interquartile
range: 67.0 to 76.8 years), and 36.7% were women.
Multiple comorbidities were present, including atrial
fibrillation in 70%. The median Society of Thoracic
Surgeons Predicted Risk of Mortality score for MV
replacement was 7.6% (interquartile range: 5.1% to
11.8%), and 76.7% were in New York Heart Association
functional class III or IV. Baseline echocardiographic
characteristics are listed in Table 2. Median left ven-
tricular ejection fraction was 46.5% (IQR: 33.4% to
55.6%). MR was the predominant pathology, present
in 56.7%.
PRIMARY SAFETY ENDPOINT AND SHORT-TERM
RESULTS. All patients were treated with transseptal
access and with the SAPIEN 3 THV. Procedural results
are presented in Table 3. The size of THV chosen ac-
cording to cardiac CT analysis coincided with the size
recommended by the MViV app in 80% of cases. A
different size than the one recommended by the
MViV app was chosen in 20% (smaller, n ¼ 2; larger,
n ¼ 4). The decision to choose a different THV size
was based on neo-annulus area by cardiac CT anal-
ysis. The THV was prepared with additional contrast
volume in the delivery balloon catheter in a majority
of cases (56.7%) to flare the THV in the left ventricle
to decrease the risk for valve embolization into the
left atrium (Figure 3). The primary safety endpoint of
technical success at exit from the procedure room was
achieved in 66.7% of patients. Reasons for not
meeting technical success criteria included need for a
second valve (n ¼ 6), mean MVG >10 mm Hg (n ¼ 1),
and MR 2þ in 3 patients, of whom 1 was treated with
paravalvular leak closure during the index procedure.
The paravalvular closure technique has been previ-
ously published (10). The reason for the need for a
second valve was a too atrial position of the THV
resulting in paravalvular leak due to lack of an inner
skirt at the annulus level (the inner skirt was mostly
on the atrial side above the annulus instead of at the
annulus) in 6 patients and invagination of native
leaflets leading to MR in 1 patient. These events
occurred early in the experience. The landing zone
was modified in subsequent cases, aiming for a more
ventricular final position of the THV (80% in the
ventricle and 20% atrial), which can be achieved by
placing the center marker of the THV 1 to 2 mm ven-
tricular to the prosthetic ring during valve deploy-
ment. After this modification, the need for a second
valve decreased. Rapid pacing and breath-hold were
recommended during deployment to increase the
probability of proper valve position. The invagination
TABLE 3 Intraprocedural Results (n ¼ 30)
Device
SAPIEN 3 30/30 (100)
Device size
23 mm 6/30 (20)
26 mm 16/30 (53.3)
29 mm 8/30 (26.7)
Access
Transeptal 30/30 (100)
Pre-dilation or balloon sizing* 11/30 (36.7)
Additional contrast during initial deployment
No 13/30 (43.3)
Yes 17/30 (56.7)
Amount (ml) 4 (0–5)
Post-dilatation 12/30 (40)
Septostomy closed 4/30 (13.3)
Results
In-hospital mortality 2/30 (6.7)
Cardiovascular 2/30 (6.7)
Noncardiovascular 0/30 (0)
Technical success at exit from catheterization laboratory 20/30 (66.7)
LVOT obstruction with hemodynamic compromise 0/30 (0)
Need for a second valve 6/30 (20)
$2 (þ) MR on procedural TEE 3/30 (10)
Paravalvular leak closure during index procedure 1/30 (3.3)
Vascular complications 0/30 (0)
Conversion to open heart surgery 0/30 (0)
Valve embolization 0/30 (0)
Left ventricular perforation 0/30 (0)
Pericardial effusion requiring pericardiocentesis 0/30 (0)
New pacemaker requirement 0/30 (0)
Myocardial infarction requiring intervention 0/30 (0)
Echocardiographic characteristics post-TMVR
Mean MVG (mmHg) 2.9 (2.3–3.9)
MVA (cm2) 2.9 (2.3–3.6)
Peak LVOT gradient (mm Hg)† 3.6 (2.4–6.6)
Mean LVOT gradient (mm Hg)† 1.8 (1.2–3.5)
Residual MR at end of procedure
Trace or none 15/30 (50.0)
1 (þ) 12/30 (40.0)
2 (þ) 3/30(10.0)
$3 (þ) 0/30 (0)
Amount of paravalvular MR at end of procedure‡
Trace or none 19/30 (63.3)
1 (þ) 8/30 (26.7)
2 (þ) 3/30 (10.0)
$3 (þ) 0/30 (0)
Values are n/N (%) or median (interquartile range). *This represents early experience and occurred
at the discretion of the operators if confirmation of sizing was desired. †Fourteen missing. ‡The
location of paravalvular leak was at commissures between the transcatheter heart valve and the
prosthetic ring (not between the prosthetic ring and the native mitral annulus).
MR ¼ mitral regurgitation; TEE ¼ transesophageal echocardiogram; TMVR ¼ transcatheter
mitral valve replacement; other abbreviations as in Tables 1 and 2.
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FIGURE 3 Additional Contrast Volume in Balloon Delivery System During Valve Deployment
(A) Transapical valve–in–mitral annular calcification procedure using a 26-mm SAPIEN XT valve prepared with a nominal amount of contrast in the balloon delivery
system resulting in a symmetrical cylinder balloon shape. (B) Transseptal mitral valve–in–ring procedure using a 29-mm SAPIEN 3 valve prepared with 4 ml additional
contrast volume in the balloon delivery system. The additional volume results in flaring of the ventricular edge of the stent frame (arrow). (C) After valve deployment,
the ventricular edge of the SAPIEN 3 stent frame diameter is larger (arrow) than the atrial edge of the stent.
CENTRAL ILLUSTRATION 30-Day and 1-Year Outcomes of Valve-in-Ring in the Mitral Implantation of
Transcatheter Valves Trial
Guerrero, M. et al. J Am Coll Cardiol Intv. 2021;14(8):846–58.
Early and late outcomes for functional capacity (New York Heart Association functional class; left), which were significantly improved at both time points versus
baseline. Walk distance (meters; median and interquartile range) on 6-min walk test (right) also improved. Early mortality (depicted as Kaplan-Meier survival;
middle) was better than expected on the basis of Society of Thoracic Surgeons score.
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of native leaflets occurred in the setting of a long
anterior leaflet overriding the ventricular edge of the
stent. This was successfully treated with a second
THV placed in a more ventricular position than the
initial THV. There were no cases of LVOT obstruction,
intraprocedural mortality, or conversion to open
heart surgery. Atrial septostomy was closed percuta-
neously in 4 patients during the index procedure
(13.3%), at the discretion of the operator because of a
large left-to-right shunt in 3 patients and thrombus in
a right atrial pacemaker lead in 1 patient.
ADDITIONAL ENDPOINTS. The primary THV perfor-
mance endpoint of absence of MR grade 2þ or greater
or mean MVG $10 mm Hg was achieved in 85.7% of
the 28 survivors at 30 days (24 of 28) and 89.5% of
patients alive at 1 year with echocardiographic data
available (17 of 19). The secondary safety endpoint of
procedural success was achieved in 22 patients
(73.3%). Reasons for not achieving procedural success
in 8 subjects included death (n ¼ 2), mean MVG
10 mm Hg (n ¼ 4), hemolysis requiring paravalvular
leak closure attempt followed by conventional MV
surgical replacement (n ¼ 1), and intracranial hem-
orrhage without neurological sequelae (n ¼ 1). All-
cause mortality at 30 days was 6.7% and at 1 year
was 23.3%. The Kaplan-Meier survival curve is pre-
sented in Figure 3 and the Central Illustration.
30-DAY OUTCOMES. At 30-day follow-up, 93.3% of
the patients were alive (28 of 30) and 75% were in
New York Heart Association functional class I or II.
The 2 deaths observed within 30 days occurred during
the index hospitalization, one due to heart failure
decompensation and the other to THV migration after
chest compressions during cardiopulmonary resusci-
tation for an aspiration event resulting in respiratory
arrest. This patient had undergone uneventful MViR
in a semirigid ring and met the criteria for technical
success. The valve migration after chest compres-
sions caused significant MR, treated with a para-
valvular leak closure procedure and transseptal
MViV. The patient died 2 days later of ventricular
fibrillation cardiac arrest. Clinical events at 30 days
and 1 year are presented in Table 4 and echocardio-
graphic characteristics in Table 5. Only 1 patient had a
stroke (3.3%), which was a spontaneous intracranial
hemorrhage during the index hospitalization in a pre-
existing, previously undiagnosed brain tumor. The
event did not result in clinical sequalae. One patient
underwent septostomy closure between discharge
and 30-day follow-up, due to heart failure attributed
to a left-to-right shunt. Two patients (6.7%) required
MV reintervention: 1 paravalvular leak closure
attempt followed by surgical MV replacement for
hemolytic anemia and 1 transseptal MViV plus para-
valvular leak closure for MR related to valve migra-
tion. Hemolytic anemia was rare and was present in
only 1 patient within 30 days (3.3%). There were no
THV thromboses or endocarditis events.
30-DAY OUTCOMES IN PATIENTS WHO NEEDED A
SECOND VALVE DURING THE INDEX PROCEDURE.
Although the 6 patients who needed a second valve
during the index procedure to treat MR resulting from
a too atrial position of the THV did not meet criteria
for technical success, there were no adverse conse-
quences. All of them were alive at 30 days and met
the criteria for device success, procedural success,
and the primary THV performance endpoint.





All-cause mortality 2/30 (6.7) 7/30 (23.3)
Cardiovascular 2/30 (6.7) 2/30 (6.7)
Noncardiovascular 0/30 (0) 5/30 (16.7)
Device success 22/30 (73.3) NA
Procedural success 22/30 (73.3) NA
Primary performance endpoint in survivors at 30 days and 1 yr 24/28* (85.7) 17/19† (89.5)
Stroke 1/30 (3.3) 1/30 (3.3)
Ischemic 0/30 (0) 0/30 (0)
Hemorrhagic‡ 1/30 (3.3) 1/30 (3.3)
Myocardial infarction requiring revascularization 0/30 (0.0) 0/30 (0.0)
Mitral valve reintervention after index procedure§ 2/30 (6.7) 3/30 (10)
Septostomy closed|| 5/30 (16.7) 7/30 (23.3)
Acute kidney injury requiring hemodialysis 3/30 (10) 4/30 (13.3)
Blood transfusion 9/30 (30) 12/30 (40)
Vascular complication¶ 2/30 (6.7) 2/30 (6.7)
New permanent pacemaker requirement 0/30 (0) 0/30 (0)
New-onset atrial fibrillation# 1/30 (3.3) 1/30 (3.3)
Patients rehospitalized for heart failure 0/30 (0) 5/30 (16.7)
Hospitalization for heart failure events 0/30 (0) 6/30 (20)
Device embolization or migration** 1/30 (3.3) 1/30 (3.3)
Hemolytic anemia†† 1/30 (3.3) 3/30 (10)
Valve thrombosis 0/30 (0) 0/30 (0)
Endocarditis 0/30 (0) 0/30 (0)
New York Heart Association functional class
I 9/28* (32.1) 7/19† (36.8)
II 12/28 (42.9) 9/19 (47.4)
III 7/28 (25) 3/19 (15.8)
IV 0/28 (0) 0/19 (0)
Values are n/N (%). *2 died within 30 days. †7 died, 1 lost to follow-up, and 3 alive at 1 yr missed 1-yr follow-up.
‡Spontaneous bleeding in a previously undiagnosed pre-existing brain tumor during the index hospitalization. §1
PVL closure attempt followed by surgical MVR and 1 transseptal mitral valve–in–valve plus PVL closure within
30 days. 1 PVL closure between 30 days and 1 yr. ||4 during index procedure, 1 between discharge and 30-day
follow up, 2 between 30-day and 1-yr follow-up. ¶Retroperitoneal bleeding during index hospitalization. #After
open heart surgery in a patient who underwent conventional surgical MVR because of PVL. **After chest com-
pressions during cardiopulmonary resuscitation for an aspiration event resulting in respiratory arrest. Device
migration caused PVL. The patient underwent PVL closure. ††1 prior to discharge treated with PVL closure
attempt followed by surgical MVR. One more after 30 days treated conservatively.
MVR ¼ mitral valve repair; NA ¼ not applicable; PVL ¼ paravalvular leak.
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1-YEAR OUTCOMES. At 1 year follow-up (median 1.0
year; interquartile range: 1.0 to 1.2 years), 76.7% of
the patients (23 of 30) were alive, and 84.2% were in
New York Heart Association functional class I or II. A
total of 5 deaths occurred between 30-day and 1-year
follow-up; all were adjudicated as noncardiovascular.
A descriptive summary of each patient, including
essential baseline characteristics and outcomes, is
provided in Table 6. A total of 5 patients had reho-
spitalizations for heart failure, 2 of them attributed to
pre-existing underlying systolic or diastolic heart
failure, 1 suspected to be secondary to paravalvular
leak treated with percutaneous paravalvular leak
closure, and 2 with suspected contribution from left-
to-right shunts who underwent percutaneous closure
of the iatrogenic interatrial septal defect. Additional
adverse events were rare. There were no strokes after
30 days. Two patients were found to have hemolytic
anemia after 30 days and were treated conservatively.
There were no late migration or embolization events,
THV thrombosis, or endocarditis. Patients who were
alive at 1 year experienced significant improvement
in New York heart Association functional class and in
6-min walk distance (Central Illustration), as well as
quality-of-life scores (Figure 4). Most patients
continued oral anticoagulation (Figure 5). The vast
majority (70%) had atrial fibrillation at baseline as the
main indication for long-term anticoagulation.
Because of unknown risk for THV thrombosis, the
investigators elected to continue anticoagulation in
the remaining patients if no bleeding complications
were present. Left ventricular function remained
unchanged. TMVR device function remained stable
with a median mean MVG of 6.0 mm Hg (interquartile
range: 4.7 to 7.3 mm Hg) in the entire cohort, but
mean MVG tended to be greater with the smaller 23-
mm THVs (median 9.3 mm Hg; IQR: 6.0 to
14.5 mm Hg) (Figure 6). However, the high gradient in
this group was driven by 1 patient treated with a 23-
mm THV in a rigid ring (26-mm ET Logix) who had a
mean MVG of 20 mm Hg at 30 days and 1 year. All
patients had 1þ or less total MR at 1 year.
DISCUSSION
This is the first prospective, multicenter, early feasi-
bility clinical trial with independent imaging core
laboratories and independent clinical event adjudi-
cation to evaluate the safety and feasibility of trans-
septal MViR using the SAPIEN 3 balloon-expandable
aortic THV. The following were the main findings: 1)
transseptal MViR in carefully selected patients was
associated with 30-day mortality lower than pre-
dicted by the Society of Thoracic Surgeons score; 2)
transseptal MViR was associated with significantly
reduced symptoms, improved 6-min walk distance,
and improved quality-of-life scores; 3) THV perfor-
mance was acceptable and remained stable in survi-
vors at 1 year; 4) in this high-risk patient cohort,
mortality at 1 year was similar to the reported mor-
tality after transcatheter MV repair with the MitraClip
or TMVR with THVs designed for the MV.
Our results differ from those of prior retrospective
studies that evaluated the early experience of MViR
procedures and demonstrated higher rates of
procedure-related complications and mortality. The
initial 30-day mortality rate in the VIVID registry was
11.4% in a patient population with a Society of
Thoracic Surgeons score of 11% (2). A recent report
from the same registry revealed a lower 30-day
mortality rate of 8.5%, but the Society of Thoracic
Surgeons score of these patients was also lower
(7.4%) (11). Similarly, the initial 30-day mortality in
the TVT Registry was 11.5% (3). These retrospective
studies evaluated outcomes using first- and second-
generation devices, and transapical access was used
in a large proportion of these patients (50.7% and
35.8%, respectively) (3,11). With careful patient se-
lection, the use of a third-generation device, and
transseptal access in all cases, we found a 30-day
mortality rate of 6.7% in a patient population with
a median Society of Thoracic Surgeons score of 7.6%.
TABLE 5 Echocardiographic Characteristics at 30 Days and 1 Year
30 Days* (n ¼ 28) 1 Year† (n ¼ 19)
Ejection fraction (%) 48.3 (39.1–52.2) 40.0 (32.7–57.5)
Stroke volume (ml) 68.2 (52.2–95.7) 75.9 (66.3–85.5)
Cardiac output (l/min) 5.0 (3.7–6.9) 5.0 (3.8–5.4)
Mean MVG (mm Hg) 7.6 (5.9–9.1) 6.0 (4.7–7.3)
MVA (cm2)‡ 2.1 (1.8–2.6) 2.4 (1.8–2.9)
Pulmonary artery systolic pressure (mm Hg) 44.4 (42.7–56.7)§ 37.6 (33.4–52.5)||
Peak LVOT gradient 4.6 (2.9–6.7) 4.3 (2.5–5.2)
Mean LVOT gradient 2.7 (1.6–3.7) 2.1 (1.4–3.1)
Severity of total mitral regurgitation
None to trace 22/28 (77.7) 11/19 (57.9)
1 (þ) 6/28 (22.2) 8/19 (42.1)
2 (þ) 0/28 (0) 0 (0)
$3 (þ) 0/28 (0) 0 (0)
Severity of paravalvular mitral regurgitation
None to trace 23/28 (81.5) 17/19 (89.5)
1 (þ) 5/28 (18.5) 2/19 (10.5)
2 (þ) 0/28 (0) 0/19 (0)
$3 (þ) 0/28 (0) 0/19 (0)
Values are median (interquartile range) or n/N (%). *2 died within 30 days. †7 died, 1 lost to follow-up, and 3 alive
at 1 yr but missed 1-yr follow-up echocardiography. ‡Uncertain reliability; standard echocardiographic methods
are validated in rheumatic disease and not mitral annular calcification or after transcatheter mitral valve
replacement. §5 missing values. ||3 missing values.
Abbreviations as in Table 2.
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The improved mortality was achieved with meticu-
lous evaluation of the anatomy using cardiac CT
imaging to determine suitability for MViR (12). The
cardiac CT analysis helped us identify patients at risk
for complications such as device embolization and
LVOT obstruction, who were not accepted into the
trial. Cardiac CT imaging was also used for pre-
procedural planning (7). Unlike retrospective regis-
tries, this selection process led to a very low rate of
procedure-related complications. There were no
intraprocedural deaths, THV device embolization,
LVOT obstruction, or conversion to open heart sur-
gery events during the index procedure.
The technical success rate was low (66.7%). This
was driven primarily by the need for a second valve in
6 patients during the index procedure to treat MR
resulting from a too atrial position of the THV. There
were no adverse clinical consequences in these 6
patients. All of them were alive at 30 days and met
the criteria for device success, procedural success,
and the primary THV performance endpoint. The
long-term effects of requirement for second valve are
not known. Three of these patients had non-
cardiovascular death at 1 year, 1 was alive at 1 year but
did not undergo echocardiography, and the other 2
were alive and met the primary THV performance
endpoint by echocardiography at 1 year.
MORTALITY AND HOSPITALIZATION FOR HEART
FAILURE AT 1 YEAR. The mortality rate at 1 year was
23.3%, which compares favorably with the 25.8%
TABLE 6 Summary of Individual Patient Data
Patient # Sex
Age











1 F 86 St. Jude Tailor Band 29 MS 29 522 26
2 M 74 Edwards Classic 28 MS 23 386 23
3 M 64 Edwards ET Logix 28 MS 26 396 23
4 M 66 St. Jude Seguin 28 MR 26 610 26
5 M 77 Medtronic CG Future Band 34 MS 29 607 29
6 F 67 Medtronic CG Future Ring 30 MR 26 542 26
7 M 71 Edwards Classic 28 MR 23 357 26
8 M 78 Edwards Classic 30 MR 26 494 26
9 F 69 Edwards Physio (number not specified) 30 Mixed 26 496 26
10 M 67 Medtronic Simulus SemiRigid 28 MR 23/26 485 26
11 F 56 Edwards Physio 28 Mixed 26 444 26
12 M 72 Duran AnCore 29 MS NA 434 26
13 M 83 Edwards Classic 30 MR 26 461 26
14 M 70 Edwards Physio 1 (4450) 30 Mixed 26 511 26
15 M 76 Medtronic GC Future Ring 36 MR 29 695 29
16 F 74 Physio I 28 MS 26 455 26
17 M 92 Physio II 26 MR 23 354 23
18 M 60 Sorin Memo 3D 28 MS 26 410 26
19 F 55 Physio 26 MS 23 381 23
20 M 58 Cosgrove band 28 MR 29 365 29
21 M 74 St. Jude Seguin 30 MR 26 533 29
22 F 70 Physio 26 MS 23 358 23
23 F 69 Physio 1 26 MR 23 362 23
24 F 82 Physio 28 MR 26 455 26
25 M 63 Medtronic CG Future Band 32 MR 26/29 735 29
26 M 74 Medtronic CG Future Ring 30 MR 26 521 29
27 M 74 Carbomedics Sorin Annuloflex 28 MS 23 503 29
28 M 79 Physio I 30 MR 26 394 26
29 F 67 Seguin 28 MR 26 477 26
30 F 84 Physio II 32 MR 29 590 29
CT ¼ computed tomography; ICH ¼ intracranial hemorrhage; MR ¼ mitral regurgitation; MS ¼ mitral stenosis; MVG ¼ mitral valve gradient; MViV ¼ mitral valve–in–valve; MVR ¼ mitral valve
replacement; NA ¼ not available; PVL ¼ paravalvular leak; THV ¼ transcatheter heart valve.
Continued on the next page
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1-year morality rate among patients treated with
transcatheter MV edge to edge repair with the
MitraClip in the United States (primary MR, 24.7%;
secondary MR, 31.2%) (13). Similarly, the mortality
observed in our study compares favorably with
outcomes of TMVR studies evaluating THVs
designed for the MV. The 30-day (6.7%) and 1-year
(23.3%) all-cause mortality rates of transseptal
MViR in this study were similar to or lower than the
30-day (6%) and 1-year (26%) mortality rates re-
ported for the initial feasibility study of the Tendyne
transcatheter valve system (Abbott Structural Heart,
Santa Clara, California) (14) and similar to or lower
than the initial experience with the Intrepid TMVR
system (Medtronic, Redwood City, California), which
showed a 30-day mortality rate of 14% and a 1-year
mortality rate of 23.8% (15). Achieving 1-year mor-
tality similar to that shown for a well-established
and safe procedure such as transcatheter edge-to-
edge MV repair or early experience with TMVR is
encouraging and demonstrates this to be a treatment
option for carefully selected patients.
The composite rate of death or hospitalization for
heart failure at 1 year of 40% was comparable with the
37.9% rate observed after MitraClip implantation in




Need for Second Valve or











Endpoint Met at 1 Year
1 No Yes Yes Yes Yes No NA (died prior to 1 yr)
2 No Yes Yes Yes Yes No NA (died prior to 1 yr)
3 Yes No Yes No (mean MVG 10 mm Hg) No (mean MVG 10 mm Hg) Yes No (mean MVG 10 mm Hg)
4 Yes No Yes Yes Yes Yes Yes
5 No Yes Yes Yes Yes Yes Alive at 1 yr but missed
1-yr visit
6 Yes No Yes No (ICH) Yes Yes Alive at 1 yr but missed
1-yr visit
7 Yes No Yes No (mean MVG 10 mm Hg) No (mean MVG 10 mm Hg) Yes Yes
8 Yes No Yes Yes Yes Yes Yes
9 Yes No Yes Yes Yes Yes Yes
10 No No (PVL closure) No No (THV migration required
MViV)
NA (died) No NA (died prior to 1 yr)
11 Yes No Yes Yes Yes Yes Yes
12 Yes No Yes Yes Yes Yes Yes
13 No No, 2 (þ) MR No No (died) NA (died) No NA (died prior to 1 yr)
14 Yes No Yes Yes Yes Yes Yes
15 No No, 2 (þ) MR Yes Yes Yes Yes Yes
16 Yes No Yes Yes Yes Yes Alive at 1 yr but missed 1-
yr visit
17 Yes No Yes No (mean MVG 10 mm Hg) No (mean MVG 10 mm Hg) No NA (died prior to 1 yr)
18 No No, 2 (þ) MR and PVL closure Yes No (mean MVG 10 mm Hg) No (mean MVG 10 mm Hg) No NA (died prior to 1 yr)
19 Yes No Yes Yes Yes Yes Yes
20 Yes No Yes Yes Yes Yes Yes
21 Yes No Yes Yes Yes Yes Yes
22 Yes No Yes Yes Yes Yes Yes
23 Yes No Yes Yes Yes Yes No (mean MVG 10 mm Hg)
24 Yes No Yes Yes Yes Yes Yes
25 No Yes Yes Yes Yes Yes Yes
26 Yes No Yes No (hemolysis, surgical
MVR)
Yes Yes NA (lost to follow-up)
27 Yes No Yes Yes Yes Yes Yes
28 No Yes Yes Yes Yes Yes Yes
29 Yes No Yes Yes Yes Yes Yes
30 No Yes Yes Yes Yes No NA (died prior to 1 yr)
TABLE 6 Continued
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rate in the control arm of MITRA-FR (Multicentre
Study of Percutaneous Mitral Valve Repair MitraClip
Device in Patients With Severe Secondary Mitral
Regurgitation) trial (13,16).
THV PERFORMANCE ENDPOINT. The primary THV
performance endpoint of absence of MR grade 2þ or
greater or mean MVG $10 mm Hg was achieved in
89.5% of patients alive with echocardiographic data
available at 1 year (17 of 19). This finding is encour-
aging considering the round shape of the aortic THV
and the variety of different shapes of surgical rings,
with some of them being incomplete, as well as the
different degrees of rigidity, which could result in
higher rates of device migration or residual para-
valvular leak. However, we excluded rigid rings after
1 rigid ring resulted in a high residual gradient early in
this experience. It is important to avoid rigid rings in
these procedures, as they can be associated with high
residual gradients and a greater degree of para-
valvular leak at commissures.
It is possible that a significant survivorship bias is
present, as patients who died prior to 1-year follow-
up could have had poorer THV performance.
Although 3 of the 5 patients who died between
30 days and 1 year met the THV performance
endpoint at 30 days, it is unknown if they developed
MR or stenosis prior to their deaths.
Although the mean MVG was higher than reported
for THVs designed for the mitral position (6.9 
4.0 mm Hg vs. 3.0  1.1 mm Hg) (14), it was similar to
the 6.5  3.1 mm Hg gradient seen at 1 year in the
VIVID registry (11). However, gradients tended to be
higher with smaller size (23-mm) THVs, particularly
in a rigid ring. The higher gradient likely reflects an
element of patient-prosthesis mismatch inherent to
placement of transcatheter valves in relatively un-
dersized annuloplasty rings.
SPECIAL ANATOMIC CONSIDERATIONS. MViR is
not ideal in rigid rings, as they could cause
underexpansion of the THV, leading to higher re-
sidual MVGs as observed in the 1 rigid ring treated
with a small THV in this study. Similarly, incom-
plete flexible rings are not ideal, because of higher
risk for THV embolization, unless there is signifi-
cant calcification and/or stenosis as underlying pa-
thology, which could help anchor the THV. In
general, we believe that rigid rings should be
avoided, particularly when a small THV is needed.
STUDY LIMITATIONS. This was an early feasibility
study with a small number of patients enrolled.
Because it was not randomized and controlled, the
results cannot provide evidence that MV intervention
FIGURE 4 Quality-of-Life Scores
Error bars represent interquartile range (IQR). KCCQ ¼ Kansas City Cardiomyopathy
Questionnaire.
FIGURE 5 Percentage of Patients Receiving Oral Anticoagulation
ViR ¼ valve-in-ring.
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in patients with failed surgical repair is associated
with decreased mortality. In addition, it is possible
that survivorship bias may have contributed to high
rates of patients’ meeting criteria for adequate THV
performance at 1 year. Last, the patient population in
our study was highly selected. Although the screen
failure rate for cases presented in case-review con-
ference calls was only 16.7%, it is possible that the
real screen failure rates at individual sites were
greater prior to case presentation. The participating
investigators are highly experienced; it is possible
that they elected not to present patients with rigid
rings at risk for THV underexpansion causing residual
gradients or incomplete bands at risk for THV embo-
lization. Therefore, our results cannot be applied to
the general population and do not support the wide-
spread application of these procedures. Careful pa-
tient selection is essential to reproduce the results
presented herein. Furthermore, MViR procedures
have not been approved by the U.S. Food and Drug
Administration and remain “off label” in the
United States.
CONCLUSIONS
In patients at high surgical risk, transseptal MViR was
associated with a 30-day mortality rate lower than
predicted by the Society of Thoracic Surgeons score.
At 1 year, transseptal MViR was associated with
symptom alleviation and stable THV performance.
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FIGURE 6 Mean Mitral Valve Gradient at 1 Year Follow-Up According to Transcatheter
Heart Valve Size
PERSPECTIVES
WHAT IS KNOWN? Repeat MV surgery is associated with
higher mortality than the risk associated with a first mitral
operation.
WHAT IS NEW? Transseptal MViR in patients at high surgical
risk with symptomatic MV disease due to failed surgical repair
with an annuloplasty ring was associated with a 30-day mortality
rate lower than predicted by the Society of Thoracic Surgeons
score. At 1 year, patients experienced sustained reduction of
symptoms and stable THV performance.
WHAT IS NEXT? Further studies are needed to refine the
screening process to further improve patient selection and pro-
cedural results and to evaluate the long-term outcomes of these
procedures.
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